Taiho signs deal to acquire Cullinan Pearl for up to $405m
On Taiho acquiring Cullinan Pearl, Cullinan Oncology is entitled to receive $275m in upfront payment.
Oncology
Latest in
Oncology
BridgeBio and BMS partner to develop BBP-398 for cancer
Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.
Twist Bioscience and Astellas to develop tumour-targeting antibodies
Astellas will handle the development, production and marketing of any licenced products developed out of the partnership.
University of Surrey scientists unveil new approach to treat brain tumours
The research project was conducted in partnership with the universities of Surrey, Leeds and Texas, as well as HOX Therapeutics.
EC approves Novartis’ Kymriah for follicular lymphoma in adults
The EC approval is based on the international Phase II ELARA clinical trial of Kymriah.
FDA’s complete response letter may cost HUTCHMED nearly $100m in potential sales
The US FDA has rejected a new drug application (NDA) from HUTCHMED for surufatinib for advanced neuroendocrine tumours (NETs).
By
Tislelizumab makes headway towards approval in ESCC but faces tough competition
Tislelizumab has been making strides towards approval for the treatment of second-line oesophagal squamous cell carcinoma (ESCC).
By
Access to CAR-T therapies in Central and Eastern Europe in “catch-up” mode compared to the West
Although some countries are moving ahead, the use of CAR-T therapies in the region remains uneven.
By